Lumos Diagnostics Holdings Ltd has released a press release.
Publication of Data from DISRUPT Clinical Trial in JAMA
Filed with ASX ·
Watch Lumos Diagnostics' latest callLumos Diagnostics Holdings (ASX:LDX) Q3 2026 Earnings Call · Replay · Apr 20Read the transcript of Lumos Diagnostics Holdings (ASX:LDX) Q3 2026 Earnings Call6ix hasn’t read this filing yet.
Lumos Diagnostics Holdings Ltd. on 6ix
Earlier from Lumos Diagnostics
- Lumos Completes Closure of Sarasota Facility
- Outcome of Appeal to FDA for FebriDx
- FY22 Full Year Results Media Release
- FY22 Full Year Results Investor Presentation
- FY22 Annual Report
Later from Lumos Diagnostics
- LDX signs agreement to raise $8m & announces General Meeting
- Lumos Secures Two Service Agreements With Hologic
- Lumos Diagnostics FY23 First Half Year Results
- Lumos signs three new agreements with Hologic
- Lumos Receives US FDA Clearance for FebriDx
Follow Lumos Diagnostics into a list and get an email when it puts out news.
Follow Lumos Diagnostics